The Methyl CpG Binding Protein 2 pipeline drugs market research report outlays comprehensive information on the Methyl CpG Binding Protein 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Methyl CpG Binding Protein 2 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Central Nervous System, and Genetic Disorders which include the indications Rett Syndrome, Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy), and X Chromosome Disorders. It also reviews key players involved in Methyl CpG Binding Protein 2 targeted therapeutics development with respective active and dormant or discontinued products.
The Methyl CpG Binding Protein 2 pipeline targets constitutes close to 11 molecules. Out of which, approximately 11 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 2, 5, and 4 respectively.
Methyl CpG Binding Protein 2 overview
Methyl CpG Binding Protein 2 (MECP2) is a chromosomal protein that binds to methylated DNA. It can bind specifically to a single methyl-CpG pair. It mediates transcriptional repression through interaction with histone deacetylase and the corepressor SIN3A, and binds both 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC)-containing DNA, with a preference for 5mC.
For a complete picture of Methyl CpG Binding Protein 2’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.